 BOSTON and LOUISVILLE, Ky., May 06, 2021 GLOBE NEWSWIRE -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the pricing of its initial public offering of 8,825,000 shares of common stock at a price to the public of 17.00 per share. All shares are being offered by Talaris. The gross proceeds to Talaris from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately 150.0 million. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol TALS on May 7, 2021. The offering is expected to close on May 11, 2021, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 1,323,750 shares of common stock at the initial public offering price less underwriting discounts and commissions. 